Coherus BioSciences, Inc. (CHRS): Price and Financial Metrics

CHRS POWR Grades

• CHRS scores best on the Value dimension, with a Value rank ahead of 95.18% of US stocks.
• The strongest trend for CHRS is in Momentum, which has been heading down over the past 48 weeks.
• CHRS ranks lowest in Growth; there it ranks in the 6th percentile.

CHRS Stock Summary

• Of note is the ratio of Coherus BioSciences Inc's sales and general administrative expense to its total operating expenses; just 15.08% of US stocks have a lower such ratio.
• Over the past twelve months, CHRS has reported earnings growth of -168.98%, putting it ahead of just 12.33% of US stocks in our set.
• Revenue growth over the past 12 months for Coherus BioSciences Inc comes in at -19.03%, a number that bests only 12.94% of the US stocks we're tracking.
• Stocks that are quantitatively similar to CHRS, based on their financial statements, market capitalization, and price volatility, are EIGR, MCRB, SVRA, CTMX, and BLCM.
• CHRS's SEC filings can be seen here. And to visit Coherus BioSciences Inc's official web site, go to www.coherus.com.

CHRS Valuation Summary

• CHRS's price/sales ratio is 3.1; this is 18.42% lower than that of the median Healthcare stock.
• Over the past 83 months, CHRS's price/sales ratio has gone down 12.5.
• Over the past 83 months, CHRS's price/sales ratio has gone down 12.5.

Below are key valuation metrics over time for CHRS.

CHRS Growth Metrics

• Its year over year revenue growth rate is now at 1.73%.
• The 2 year cash and equivalents growth rate now stands at 135.47%.
• Its 2 year net cashflow from operations growth rate is now at 161.53%.

Over the past 33 months, CHRS's revenue has gone up $394,647,000.

The table below shows CHRS's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2021-06-30	394.647	81.656	-165.206
2021-03-31	442.678	142.035	-76.275
2020-12-31	475.824	154.145	132.244
2020-09-30	489.261	138.731	161.763
2020-06-30	487.394	146.329	180.873
2020-03-31	435.153	98.815	145.409

CHRS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• CHRS has a Quality Grade of B, ranking ahead of 81.32% of graded US stocks.
• CHRS's asset turnover comes in at 0.513 -- ranking 81st of 677 Pharmaceutical Products stocks.
• CPRX, XTNT, and ONCT are the stocks whose asset turnover ratios are most correlated with CHRS.

The table below shows CHRS's key quality metrics over time.